CXCR5 and neoplasm: CXCR5 is particularly suitable as target in CAR-T cell therapy of lymphoma because of a threefold therapeutic mechanism, namely (i) prevention of tumor cell homing, (ii) direct lymphoma cell elimination, and (iii) abrogation of a tumor-promoting stroma function.